Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

NCT00132496 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG: rabeprazole sodium

Sponsor

Eisai Inc.